Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Retained Earnings (2016 - 2025)

IGC Pharma (IGC) has disclosed Retained Earnings for 15 consecutive years, with -$4.9 million as the latest value for Q3 2025.

  • Quarterly Retained Earnings rose 95.88% to -$4.9 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was -$4.9 million through Sep 2025, up 95.88% year-over-year, with the annual reading at -$120.7 million for FY2025, 6.23% down from the prior year.
  • Retained Earnings for Q3 2025 was -$4.9 million at IGC Pharma, down from -$3.5 million in the prior quarter.
  • The five-year high for Retained Earnings was -$2.8 million in Q1 2021, with the low at -$120.7 million in Q1 2025.
  • Average Retained Earnings over 5 years is -$49.3 million, with a median of -$4.9 million recorded in 2025.
  • The sharpest move saw Retained Earnings tumbled 3114.1% in 2022, then surged 96.46% in 2023.
  • Over 5 years, Retained Earnings stood at -$82.7 million in 2021, then dropped by 16.91% to -$96.6 million in 2022, then soared by 96.46% to -$3.4 million in 2023, then fell by 0.99% to -$3.5 million in 2024, then crashed by 40.33% to -$4.9 million in 2025.
  • According to Business Quant data, Retained Earnings over the past three periods came in at -$4.9 million, -$3.5 million, and -$120.7 million for Q3 2025, Q2 2025, and Q1 2025 respectively.